Dosing and administration
This unit explains, for education only, how thymosin alpha-1 is delivered, what its pharmacokinetics look like, and how…
How it is given, and why the numbers are education only
This unit explains, for education only, how thymosin alpha-1 is delivered, what its pharmacokinetics look like, and how to read the regimens quoted in trials and online. It exists so you can interpret the literature critically, not so you can act on any number.
Nothing here is a protocol, a dose, or a recommendation to use thymosin alpha-1. It is not FDA-approved, and any real decision belongs with a licensed clinician who can weigh an individual situation.
Key terms
Routes of administration
Because Tα1 is a peptide, the route matters and oral use is a non-starter: digestion would destroy it. The registered route is subcutaneous injection, with intravenous and intramuscular use appearing in some studies. Route shapes both how the drug behaves and how much evidence stands behind it.
The practical lesson is that injection is intrinsic to this molecule, not a preference. A peptide this size cannot survive the gut and reach the blood intact, which is exactly why every credible study uses an injected route and why "oral thymosin alpha-1" claims deserve immediate skepticism.
AdvancedWhy peptides resist oral dosing
Small peptides are cleaved by stomach acid and gut proteases and absorb poorly across the intestinal wall, so oral bioavailability is negligible. This is a general rule for therapeutic peptides, not a Tα1 quirk. It is also why sustained-release depot formulations (for example PLGA in-situ implants) have been explored preclinically: to extend exposure without frequent injection, though these remain research-stage.